Blood Biopsies vs Bone Marrow Biopsies – The Good News For The Week …
Antibody-Drug Conjugates and Multiple Myeloma
MCRT Review: St Louis, Missouri – March 10, 2018
Only Your Genes Will Tell
Patient Power: How Can Myeloma Patients Combat Neuropathy?
First Risk-Adapted Therapy Trial for Newly Diagnosed Patients (the MASTER trial) with Luciano Costa, MD, PhD, UAB
Dr. Costa shares a key study for newly diagnosed multiple myeloma patients
Charlotte Round Table - April 14, 2018
Researchers Suggest Increased Screening of MGUS Patients to Prevent Multiple Myeloma
Lenalidomide Every Other Day for Myeloma Patients with Kidney Concerns?
Changing Careers in Midst of Myeloma…
Neutropenia in Multiple Myeloma and What You Need to Know
Baltimore Round Table - March 28, 2018
How Do I Exercise with Myeloma If I Am Elderly or Frail?
New Drug Targeting WT1 Found to Be Effective as Post-Transplant Myeloma Therapy for High-Risk Patients
Clinical Trial: Four Drug Induction Before Transplant Using Monoclonal Antibody for Newly Diagnosed Myeloma
Patient Power: Is Sugar Part of a Myeloma-Friendly Diet?
Armored CAR-T Cells
NAM-Natural Killer Cells with Elotuzumab by Viktoria Bachanova, MD, PhD, University of Minnesota
Dr. Bachanova shares why elotuzumab is used over daratumumab.
St. Louis Round Table - March 10th, 2018
Clinical Trial: Seattle Genetics’ SGN-CD48A Phase I Study for Patients with Relapsed/Refractory Myeloma
Spotlight on Myeloma: Multiple Myeloma Awareness Month
What is CAR-T Cell Therapy? 9 Things To Know
Long-Term Follow-Up of MGUS Patients
Managing Bone Disease With Multiple Myeloma
